Dextromethorphan and guaifenesin use needs to be monitored meticulously in people with "weak metabolizer" CYP2D6 enzyme concentrations and patients who are sedated. This mix medication provides a huge median harmful dose (TD50) to median productive dose (ED50) ratio (or therapeutic index) in these sufferers. When coupled with other antidepressants, latest https://fidelv986bny8.bmswiki.com/user